Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.
Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW. Foote KM, et al. Among authors: brady mc. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1904-9. doi: 10.1016/j.bmcl.2008.02.002. Epub 2008 Feb 7. Bioorg Med Chem Lett. 2008. PMID: 18294849
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S. Mortlock AA, et al. Among authors: brady mc. J Med Chem. 2007 May 3;50(9):2213-24. doi: 10.1021/jm061335f. Epub 2007 Mar 21. J Med Chem. 2007. PMID: 17373783
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S. Wilkinson RW, et al. Among authors: brady mc. Clin Cancer Res. 2007 Jun 15;13(12):3682-8. doi: 10.1158/1078-0432.CCR-06-2979. Clin Cancer Res. 2007. PMID: 17575233
Interventions for people with perceptual disorders after stroke: the PIONEER scoping review, Cochrane systematic review and priority setting project.
Hazelton C, Todhunter-Brown A, Campbell P, Thomson K, Nicolson DJ, McGill K, Chung CS, Dorris L, Gillespie DC, Hunter SM, Williams LJ, Brady MC. Hazelton C, et al. Among authors: brady mc. Health Technol Assess. 2024 Oct;28(69):1-141. doi: 10.3310/WGJT3471. Health Technol Assess. 2024. PMID: 39485540 Free PMC article.
The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.
Sackley CM, Rick C, Brady MC, Burton C, Jowett S, Patel S, Woolley R, Masterson-Algar P, Nicoll A, Smith CH, Abdali Z, Ives N, Beaton G, Dickson S, Ottridge R, Nankervis H, Clarke CE; PD COMM Collaborative Group. Sackley CM, et al. Among authors: brady mc. Health Technol Assess. 2024 Oct;28(58):1-141. doi: 10.3310/ADWP8001. Health Technol Assess. 2024. PMID: 39364774 Free PMC article. Clinical Trial.
Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
Sackley CM, Rick C, Brady MC, Woolley R, Burton C, Patel S, Masterson-Algar P, Nicoll A, Smith CH, Jowett S, Ives N, Beaton G, Dickson S, Ottridge R, Sharp L, Nankervis H, Clarke CE; PD COMM collaborative group. Sackley CM, et al. Among authors: brady mc. BMJ. 2024 Jul 10;386:e078341. doi: 10.1136/bmj-2023-078341. BMJ. 2024. PMID: 38986549 Free PMC article. Clinical Trial.
82 results